Santa Barbara-based Naryx Pharma has received $8M in venture funding, saying this morning that it has raised a Series B2 round from Vivo Ventures and Sutter Hill Ventures. Naryx is developing proprietary products for the treatment of chronic sinusitis. The firm is heade dby Robin Campbell, former General Manager and Vice President of the Oncology Business Unit at Amgen. Chen Yu and Ed Engleman of Vivo will join the company's board of directors. More information »